Grigorios Siokas Purchases 766,284 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 766,284 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were bought at an average cost of $0.18 per share, with a total value of $137,931.12. Following the completion of the acquisition, the chief executive officer directly owned 14,248,092 shares of the company’s stock, valued at $2,564,656.56. The trade was a 5.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Grigorios Siokas also recently made the following trade(s):

• On Thursday, June 11th, Grigorios Siokas bought 218,447 shares of Cosmos Health stock. The stock was bought at an average price of $0.21 per share, for a total transaction of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas bought 701,447 shares of Cosmos Health stock. The stock was bought at an average cost of $0.23 per share, with a total value of $161,332.81.

Cosmos Health Stock Performance

COSM traded up $0.03 during mid-day trading on Thursday, reaching $0.21. 3,351,799 shares of the company traded hands, compared to its average volume of 4,598,194. The company’s fifty day moving average price is $0.23 and its 200-day moving average price is $0.33. The stock has a market capitalization of $12.49 million, a P/E ratio of -0.32 and a beta of 4.83. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. Cosmos Health Inc. has a 52-week low of $0.16 and a 52-week high of $1.32.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $17.93 million. On average, sell-side analysts expect that Cosmos Health Inc. will post 0.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cosmos Health in a report on Monday, June 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Cosmos Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Cosmos Health by 260.5% during the 4th quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after acquiring an additional 241,775 shares during the period. Citadel Advisors LLC boosted its position in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares during the period. Finally, XTX Topco Ltd boosted its position in shares of Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after purchasing an additional 34,117 shares during the period. 12.61% of the stock is currently owned by hedge funds and other institutional investors.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.